 Masanori Hayashi
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Ewing | 5 | 2021 | 62 | 1.560 |
Why?
| | Bone Neoplasms | 6 | 2023 | 194 | 1.070 |
Why?
| | Circulating Tumor DNA | 1 | 2021 | 21 | 0.750 |
Why?
| | RNA, Neoplasm | 1 | 2021 | 80 | 0.750 |
Why?
| | Pituitary Diseases | 1 | 2020 | 22 | 0.740 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 35 | 0.720 |
Why?
| | Pituitary Gland | 1 | 2020 | 152 | 0.700 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2020 | 863 | 0.690 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 192 | 0.640 |
Why?
| | Biomarkers, Tumor | 4 | 2021 | 1048 | 0.610 |
Why?
| | DNA, Neoplasm | 2 | 2023 | 157 | 0.570 |
Why?
| | Osteosarcoma | 4 | 2023 | 66 | 0.510 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 39 | 0.490 |
Why?
| | Thrombocytopenia | 1 | 2015 | 175 | 0.430 |
Why?
| | Precision Medicine | 1 | 2016 | 344 | 0.420 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 225 | 0.410 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 242 | 0.400 |
Why?
| | Hydroxyurea | 1 | 2011 | 30 | 0.390 |
Why?
| | Transfusion Reaction | 1 | 2011 | 66 | 0.380 |
Why?
| | Perioperative Care | 1 | 2011 | 126 | 0.360 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 2 | 2021 | 16 | 0.330 |
Why?
| | RNA-Binding Protein EWS | 2 | 2021 | 16 | 0.330 |
Why?
| | Translocation, Genetic | 2 | 2021 | 93 | 0.320 |
Why?
| | Anemia, Sickle Cell | 1 | 2011 | 217 | 0.310 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1000 | 0.300 |
Why?
| | Sarcoma | 3 | 2020 | 137 | 0.300 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 178 | 0.280 |
Why?
| | Prognosis | 5 | 2023 | 3339 | 0.230 |
Why?
| | Child | 10 | 2022 | 18489 | 0.220 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2023 | 27 | 0.210 |
Why?
| | Fertility Preservation | 1 | 2022 | 47 | 0.200 |
Why?
| | Mice, SCID | 3 | 2016 | 321 | 0.190 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 850 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1361 | 0.180 |
Why?
| | Rhabdomyosarcoma | 2 | 2020 | 52 | 0.180 |
Why?
| | Mice, Inbred NOD | 3 | 2016 | 560 | 0.180 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 59 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 167 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 501 | 0.150 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 704 | 0.140 |
Why?
| | Cyclophosphamide | 1 | 2017 | 218 | 0.140 |
Why?
| | Calmodulin-Binding Proteins | 1 | 2016 | 12 | 0.140 |
Why?
| | Neoplasms | 2 | 2022 | 2118 | 0.140 |
Why?
| | Bone Marrow Transplantation | 1 | 2017 | 239 | 0.130 |
Why?
| | Radiotherapy | 1 | 2017 | 177 | 0.130 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 33 | 0.130 |
Why?
| | Humans | 16 | 2023 | 115589 | 0.130 |
Why?
| | Pyrazines | 1 | 2015 | 70 | 0.120 |
Why?
| | Adolescent | 5 | 2021 | 17890 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 273 | 0.120 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 350 | 0.120 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 213 | 0.120 |
Why?
| | Female | 7 | 2021 | 59913 | 0.120 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 148 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2800 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 526 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 684 | 0.110 |
Why?
| | Transcription Factors | 1 | 2021 | 1528 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2016 | 362 | 0.110 |
Why?
| | Male | 5 | 2021 | 55949 | 0.110 |
Why?
| | Glioblastoma | 1 | 2015 | 253 | 0.110 |
Why?
| | Neoplasm Staging | 1 | 2016 | 1178 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 431 | 0.100 |
Why?
| | Pyridines | 1 | 2015 | 425 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2016 | 2194 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2015 | 1083 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 1147 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1490 | 0.090 |
Why?
| | Mutation | 1 | 2020 | 3364 | 0.090 |
Why?
| | Child, Preschool | 2 | 2020 | 9133 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 1265 | 0.090 |
Why?
| | Clinical Trials as Topic | 3 | 2020 | 941 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2020 | 1872 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2015 | 980 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2015 | 3580 | 0.070 |
Why?
| | Mice | 3 | 2016 | 15052 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2017 | 9159 | 0.050 |
Why?
| | Infant | 1 | 2015 | 7979 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2023 | 12608 | 0.050 |
Why?
| | Medical Oncology | 1 | 2022 | 230 | 0.050 |
Why?
| | Animals | 3 | 2016 | 32102 | 0.050 |
Why?
| | Albumins | 1 | 2020 | 91 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 347 | 0.040 |
Why?
| | Deoxycytidine | 1 | 2020 | 140 | 0.040 |
Why?
| | Paclitaxel | 1 | 2020 | 192 | 0.040 |
Why?
| | Young Adult | 3 | 2020 | 10470 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 319 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 302 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2020 | 243 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2022 | 646 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2020 | 372 | 0.040 |
Why?
| | Transplantation, Haploidentical | 1 | 2017 | 7 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2020 | 519 | 0.030 |
Why?
| | Biological Evolution | 1 | 2020 | 417 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2016 | 166 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2016 | 135 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 119 | 0.030 |
Why?
| | Hindlimb | 1 | 2015 | 125 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 480 | 0.030 |
Why?
| | beta Catenin | 1 | 2016 | 220 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1127 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 930 | 0.030 |
Why?
| | Patient Care Team | 1 | 2017 | 521 | 0.030 |
Why?
| | Adult | 3 | 2020 | 30719 | 0.030 |
Why?
| | Cell Survival | 1 | 2015 | 1024 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2022 | 5077 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2016 | 667 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4440 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1642 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1405 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 2604 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 2751 | 0.020 |
Why?
| | Apoptosis | 1 | 2016 | 2377 | 0.020 |
Why?
|
|
Hayashi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|